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Background: This study examined if CF mutation heterozygosity is associated with diseases of gastrointestinal epithelial barrier function.
Design and methods: Swedish registers identified 865 patients with a diagnosis of CF between 1968 and 2003 and matched with 8101 individuals
without CF. Gastrointestinal disease risk was examined among 1534 biological parents and 1396 siblings of CF patients, compared with 15,526
parents and 15,542 siblings of individuals without CF.
Results: First-degree relatives of CF patients were not at lower risk of the gastrointestinal diseases, in contrast with a raised risk among CF
patients.
Conclusion: Heterozygosity for CF gene mutations does not protect against gastrointestinal diseases where impaired barrier function may be
relevant.
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While there is little evidence that increased fertility [2]
accounts for the relatively high frequency of CF gene mutations
among Caucasians, [1] there may be some protection from
gastrointestinal and other infections [3,4]. The entry of
infectious agents into epithelial cells is impaired in animals
heterozygous for CF polymorphisms [4]. Despite normal
intestinal chloride secretion in humans [5], improved gastroin-
testinal barrier function may theoretically contribute to
protection, including against diseases involving an immune
response against luminal contents (such as bacteria) including
peptic ulcer [6], coeliac disease, ulcerative colitis and Crohn's⁎ Corresponding author. Clinical Epidemiology Unit, Department of Medi-
cine, Karolinska Institutet, Karolinska Hospital, SE-171 76 Stockholm, Sweden.
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doi:10.1016/j.jcf.2010.03.010disease [7]. We examined the risk of these diseases in first-
degree relatives of CF patients as the majority would be
heterozygous for CF mutations and compared them with
relatives of a matched cohort without CF. To examine the
specific role of likely barrier function, diseases where barrier
function is less relevant were also investigated: pancreatic
diseases, cholelithiasis, diverticulitis, appendectomy, cholecys-
titis, and fibrosis and cirrhosis of liver. The risks for the
gastrointestinal diseases were also estimated among the CF
patients.
2. Subjects and methods
The Swedish Inpatient Register [8] identified Swedish
patients with a diagnosis of CF between 1968 and 2003 (ICD-
8 code 273.0; ICD-9 code 277.0; and ICD-10 code E84), age 60
or less at follow-up as CF patients rarely live beyond 60 years of
age [9]. The 865 patients were matched with 10 individualsd by Elsevier B.V. All rights reserved.
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sex, vital status at diagnosis and region of residence (n=8101).
The Multi-Generation Register [10] identified 759 and 7707
biological fathers, 775 and 7819 biological mothers of subjects
with and without CF, respectively. Failure to identify parents
was mainly due to births before 1932, pre-dating inclusion in
the register [10]. Some 1396 and 15,542 siblings of subjects
were identified with and without CF, respectively. The Inpatient
Register was used to identify diagnoses of gastrointestinal
diseases. This study was approved by Karolinska Institutet
regional ethics committee.3. Statistical analysis
Cox regression (SAS software) was used to estimate the risk
of the gastrointestinal diseases. Parents and siblings of patients
with a diagnosis of CF were compared with parents and siblings
of the cohort without CF. We excluded 114 siblings who also
had a CF diagnosis. Follow-up was from 1964, when the
Inpatient Register was established, or from birth or immigration
if this occurred subsequently; and continued until emigration,
death, or 31st December 2003. The underlying time scale for all
models was attained age, and adjustment was for the matching
characteristics used to define risk-sets. The Cox regression was
internally stratified by calendar period (in ten-year intervals).4. Results
The average follow-up time for parents of CF patients and
the comparison parents was over 36.0 years. Siblings of patients
with CF and comparison siblings were followed for an average
of 23.0 years. The index subjects with and without CF were
followed for averages of 21.0 and 23.5 years, respectively.Table 1
Gastrointestinal disease risk among parents of patients with cystic fibrosis (759 fath
cystic fibrosis (7707 fathers and 7819 mothers).
Mothers
Events exposed/unexposed HR 9
Diseases of impaired barrier function
Peptic ulcer 10/93 1.03
Gastric ulcer 3/47 0.64
Duodenal ulcer 4/35 1. 12
Ulcerative colitis 3/30 1.02
Crohn's disease 2/28 0.75
Coeliac disease 2/11 1.91
Other diseases
Acute pancreatitis 5/36 1.47
Other diseases of pancreas 2/7 3.07
Cholelithiasis 56/476 1.20
Diverticulitis 12/89 1.33
Appendectomy 57/482 1.20
Only appendicitis 17/242 0.70
Cholecystitis 4/61 0.66
Fibrosis and cirrhosis of liver 2/17 1.18
HR 95% CI— hazard ratio and 95% confidence interval.4.1. First-degree relatives
There was no notable risk reduction for any of the diseases
among parents (Table 1) and siblings (Table 2) of patients with
CF. In stratified analyses there was no increased or decreased
risk of the gastrointestinal diseases among mothers of those with
CF. The risks for gastric ulcer and ulcerative colitis were
statistically significantly increased among fathers of patients
with CF. There were no statistically significant associations in
siblings (Table 2). Stratification by sex did not reveal notable
associations.
Stratification by calendar year of CF diagnosis, to tackle
possible variation in diagnostic accuracy and differences in
follow-up time, did not alter any of the results notably.
4.2. Cystic fibrosis patients
Among patients with CF, we observed statistically signifi-
cant increased risks for peptic ulcer, ulcerative colitis, Crohn's
disease, coeliac disease, pancreatic diseases, cholelithiasis,
appendectomy, cholecystitis, and fibrosis and cirrhosis of the
liver, compared with individuals without CF (Table 3).
5. Discussion
Contrary to our hypothesis, there was no evidence of reduced
risk for any of the diseases among first-degree relatives of CF
patients and we identified statistically significant excess risks
for gastric ulcer and ulcerative colitis among fathers. This was
similar to our previous finding of no protective effect against
cancer in relatives of CF patients [11]. As expected, the patients
with CF in this study were at a higher risk of having a range of
gastrointestinal diseases.
The relative risks for some of the gastrointestinal diseases in
relatives were close to unity, consistent with an earlier study ofers and 775 mothers) compared with parents of the comparison group without
Fathers
5% CI Events exposed/unexposed HR 95% CI
(0.54–1.99) 21/168 1.14 (0.72–1.80)
(0.20–2.07) 15/57 2.39 (1.35–4.25)
(0.40–3.17) 5/76 0.62 (0.25–1.54)
(0.31–3.36) 8/33 2.48 (1.14–5.40)
(0.18–3.14) 1/17 0.60 (0.08–4.54)
(0.42–8.72) 0/4 –
(0.57–3.74) 7/65 1.08 (0.49–2.35)
(0.63–14.9) 4/18 2.11 (0.71–6.27)
(0.91–1.58) 21/182 1.11 (0.71–1.75)
(0.73–2.45) 8/73 1.07 (0.52–2.23)
(0.91–1.58) 29/372 0.81 (0.55–1.18)
(0.43–1.14) 23/242 0.98 (0.64–1.51)
(0.24–1.83) 3/41 0.62 (0.19–2.02)
(0.27–5.10) 3/47 0.64 (0.20–2.06)
Table 2
Gastrointestinal disease risk among siblings of patients with cystic fibrosis
(n=1396) compared with siblings of the comparison group without cystic
fibrosis (n=15,542).
Events exposed/unexposed HR, 95% CI
Diseases of impaired barrier function
Peptic ulcer 7/46 1.48 (0.66–3.34)
Only gastric ulcer 3/20 1.49 (0.43–5.13)
Only duodenal ulcer 4/20 1.97 (0.65–5.97)
Ulcerative colitis 1/36 0.34 (0.05–2.53)
Crohn's disease 4/29 1.51 (0.53–4.32)
Coeliac disease 3/31 1.08 (0.33–3.53)
Other diseases
Acute pancreatitis 4/27 1.54 (0.53–4.44)
Other diseases of pancreas 2/8 2.13 (0.43–10.55)
Cholelithiasis 16/182 0.89 (0.53–1.49)
Diverticulitis 3/30 1.04 (0.31–3.51)
Appendectomy 69/768 0.99 (0.77–1.26)
Only appendicitis 42/544 0.86 (0.63–1.17)
Cholecystitis 3/23 1.16 (0.33–4.02)
Fibrosis and cirrhosis of liver 1/14 1.03 (0.13–7.98)
HR 95% CI— hazard ratio and 95% confidence interval.
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CF gene mutations [12]. However, we cannot rule out the
possibility that a protective effect is masked by our use of a
cohort of first-degree relatives of patients with a diagnosis of CF
(rather than identifying heterozygosity through screening). It is
possible that a proportion of such individuals are compound
heterozygous for CF, and also carry a second mutation on the
other chromosome resulting in a sub-clinical or variant form ofTable 3
Gastrointestinal disease risk among patients with cystic fibrosis (n=865)
compared with the comparison group without cystic fibrosis (n=8101).
Events
among
subjects
with CF
Events
among
subjects
without CF
HR.95% CI
Diseases of impaired barrier function
Peptic ulcer 14 14 16.97 (7.83–36.81)
Ulcerative
colitis
6 16 4.98 (1.92–12.88)
Crohn's
disease
6 17 4.69 (1.83–12.03)
Coeliac
disease
30 15 21.21 (11.36–39.60)
Other diseases
Acute
pancreatitis
12 9 23.50 (8.73–63.25)
Other diseases
of pancreas
19 5 48.49 (17.81–132.06)
Cholelithiasis 28 83 5.57 (3.56–8.69)
Diverticulitis 2 13 2.64 (0.57–12.17)
Appendectomy 47 364 1.70 (1.25–2.30)
Cholecystitis 10 8 20.41 (7.63–54.59)
Fibrosis
and cirrhosis
of liver
42 10 62.14 (29.08–132.80)
HR 95% CI— hazard ratio and 95% confidence interval.CF [13] themselves, thus increasing gastrointestinal disease risk
as observed in patients with CF. The statistically significant
risks for gastric ulcer and ulcerative colitis among fathers who
were CF gene mutation carriers are not consistent with our
hypothesis, and may represent a chance finding.
Consistent with results from previous studies [13–15], the
patients with CF were at a higher risk of Crohn's disease, celiac
disease, pancreatic diseases, cholelithiasis, cholecystitis, and
fibrosis and cirrhosis of liver. In contrast with earlier reports of
lower risk of appendectomy among patients with CF [16,17] we
observed a higher risk of appendectomy among CF patients.
When we restricted the analysis to appendectomy due only to
acute appendicitis (data not shown), the raised risk was no
longer observed. The frequent examinations experienced by CF
patients may have resulted in an over-estimation of associations
with some diseases.
This study had some potential limitations. Although we had
information on all inpatients diagnosed with CF in Sweden over
a long period, the number of patients with CF remained small.
Although the DF508 mutation is the most common in CF, we
did not have information on mutation-type and could not
investigate specific associations. Diseases were identified using
the Swedish Inpatient Register, the validity of which is
generally high [18] and bias due to diagnostic misclassification,
if any, is likely to move relative risks toward the null thus
potentially masking any protective effect among first-degree
relatives.
In conclusion, we did not observe any significant risk
reduction for the gastrointestinal diseases among people
identified as likely heterozygous CF gene mutation carriers.
Patients with CF are at higher risk of hospital admission for a
variety of gastrointestinal diseases.Acknowledgment
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